Aliases & Classifications for Writing Disorder

MalaCards integrated aliases for Writing Disorder:

Name: Writing Disorder 12 14 69

Classifications:



External Ids:

Disease Ontology 12 DOID:0060047

Summaries for Writing Disorder

Disease Ontology : 12 A learning disability that involves impaired written language ability such as impairments in handwriting, spelling, organization of ideas, and composition.

MalaCards based summary : Writing Disorder is related to dysgraphia and agraphia, and has symptoms including aprosodia An important gene associated with Writing Disorder is DCDC2 (Doublecortin Domain Containing 2). The drugs Dopamine and Phosphocreatine have been mentioned in the context of this disorder. Affiliated tissues include brain, testes and liver, and related phenotypes are Decreased viability with TRAIL and behavior/neurological

Related Diseases for Writing Disorder

Graphical network of the top 20 diseases related to Writing Disorder:



Diseases related to Writing Disorder

Symptoms & Phenotypes for Writing Disorder

UMLS symptoms related to Writing Disorder:


aprosodia

GenomeRNAi Phenotypes related to Writing Disorder according to GeneCards Suite gene sharing:

26
id Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability with TRAIL GR00240-S-2 8.62 GRN MAP4K5

MGI Mouse Phenotypes related to Writing Disorder:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 9.55 DCDC2 GRN MAP4K5 PSEN1 SLC17A5
2 cellular MP:0005384 9.35 CAMP GRN MAP4K5 PSEN1 SLC17A5
3 vision/eye MP:0005391 8.92 CAMP GRN PSEN1 SLC17A5

Drugs & Therapeutics for Writing Disorder

Drugs for Writing Disorder (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 183)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dopamine Approved Phase 4,Phase 1,Phase 2 51-61-6, 62-31-7 681
2
Phosphocreatine Approved Phase 4 67-07-2 587
3
Risperidone Approved, Investigational Phase 4 106266-06-2 5073
4
Pregabalin Approved, Illicit, Investigational Phase 4 148553-50-8 5486971
5
Amoxicillin Approved, Vet_approved Phase 4,Phase 3 26787-78-0 33613 2171
6
Choline Approved, Nutraceutical Phase 4 62-49-7 305
7 Strawberry Approved, Nutraceutical Phase 4
8 Central Nervous System Depressants Phase 4,Phase 3
9 Dopamine Agents Phase 4,Phase 1,Phase 2
10 Neurotransmitter Agents Phase 4,Phase 3,Phase 1,Phase 2
11 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 1,Phase 2
12 Anti-Infective Agents Phase 4,Phase 3,Phase 1
13 Antipsychotic Agents Phase 4
14 Dopamine Antagonists Phase 4
15 Psychotropic Drugs Phase 4
16
Serotonin Phase 4 50-67-9 5202
17 Serotonin Agents Phase 4
18 Serotonin Antagonists Phase 4
19 Tranquilizing Agents Phase 4
20 Analgesics Phase 4
21 Anti-Anxiety Agents Phase 4
22 Anticonvulsants Phase 4
23 calcium channel blockers Phase 4
24 Calcium, Dietary Phase 4
25 Amoxicillin-Potassium Clavulanate Combination Phase 4
26 Anti-Bacterial Agents Phase 4,Phase 3
27 beta-Lactamase Inhibitors Phase 4
28 Clavulanic Acid Phase 4
29
Creatine Nutraceutical Phase 4 57-00-1 586
30
Peginterferon alfa-2a Approved, Investigational Phase 3 198153-51-4 5360545
31
Ribavirin Approved Phase 3 36791-04-5 37542
32
Iron Approved Phase 3 7439-89-6 23925
33
Chlorhexidine Approved, Vet_approved Phase 3 55-56-1 9552079 2713
34
Ethanol Approved Phase 3 64-17-5 702
35
Sulfamethoxazole Approved Phase 3 723-46-6 5329
36
Trimethoprim Approved, Vet_approved Phase 3 738-70-5 5578
37
Bortezomib Approved, Investigational Phase 3 179324-69-7 387447 93860
38
Busulfan Approved, Investigational Phase 3 55-98-1 2478
39
Dexamethasone Approved, Investigational, Vet_approved Phase 3 50-02-2 5743
40
Lenalidomide Approved Phase 3 191732-72-6 216326
41
Melphalan Approved Phase 3 148-82-3 4053 460612
42
Praziquantel Approved, Vet_approved Phase 3 55268-74-1 4891
43
Capecitabine Approved, Investigational Phase 3 154361-50-9 60953
44
Oxaliplatin Approved, Investigational Phase 3 61825-94-3 5310940 9887054 43805 6857599
45 Ixazomib Approved Phase 3 1072833-77-2
46 Hops Approved, Nutraceutical Phase 2, Phase 3
47
Vitamin C Approved, Nutraceutical Phase 2, Phase 3 50-81-7 5785 54670067
48
Myrrh Approved, Nutraceutical Phase 3 9000-45-7
49
Glycine Approved, Nutraceutical, Vet_approved Phase 3 56-40-6 750
50 Antimetabolites Phase 3

Interventional clinical trials:

(show top 50) (show all 259)

id Name Status NCT ID Phase Drugs
1 Janssen Asperger's MRS (Magnetic Resonance Spectroscopy Risperidone Study Completed NCT00352196 Phase 4 Risperidone
2 Organ Transplant Infection Prevention and Detection Project Completed NCT00177801 Phase 4
3 Pregabalin in the Treatment of Essential Tremor Completed NCT00646451 Phase 4 pregabalin;placebo capsules
4 Acute Otitis Media (AOM) Therapy Trial in Young Children Completed NCT00377260 Phase 4 amoxicillin-clavulanate;Placebo
5 Different Ribavirin Dosages and Different Duration of Treatment in Combination With PegInterferon in Patients With Genotype 2 and 3 (WRITE) Unknown status NCT01380938 Phase 3 Peginterferon alpha-2a + Ribavirin
6 Omega-3/Omega-6 Fatty Acids for Attention-Deficit/Hyperactivity Disorder (ADHD): A Trial in Children and Adolescents Completed NCT01219309 Phase 3
7 Military to Civilian: Trial of an Intervention to Promote Postdeployment Reintegration Completed NCT00640445 Phase 2, Phase 3
8 Adjuvant I.V. Iron Therapy During Erythropoetin Treatment of Anemic Patients With Lymphoproliferative Disorders. Completed NCT00145652 Phase 3 Neo-Recormon and Venofer
9 Brief Eclectic Psychotherapy for PTSD - a Randomized Controlled Trial Completed NCT00329992 Phase 3
10 Isopropyl Alcohol Against Chlorhexidine - Isopropyl Alcohol as Antiseptics to Prevent Hemoculture's Contamination Completed NCT01361997 Phase 3
11 ICMR-Indiaclen Trial on Amoxycillin vs Cotrimoxazole for Non-Severe Pneumonia Completed NCT00396526 Phase 3 Oral Co-trimoxazole (8mg/kg/day trimithoprim) twice a day for five days vs. oral amoxycillin (20 mg/kg/day) thrice a day for three days.
12 Bortezomib (Velcade®), Lenalidomide (Revlimid®) and IV Busulfan (Busilvex®) in Patients Under 65 Years Old Completed NCT01916252 Phase 3 bortezomib (Velcade ®);lenalidomide (Revlimid®);busulfan (Busilvex ®);Dexamethasone acetate;Melphalan
13 Music Therapy or Book Discussion in Improving Quality of Life in Young Patients Undergoing Stem Cell Transplant Completed NCT00305851 Phase 3
14 Integrative Medicine Approach to the Management of Asthma in Adults Completed NCT00843544 Phase 2, Phase 3
15 Safety and Efficacy of Mirazid for Schistosomiasis Treatment Completed NCT01529710 Phase 3 Myrrh
16 Clinical Trial of Efficacy and Safety of Tenoten for Children in the Treatment of Specific Developmental Disorders of Scholastic Skills in Children Recruiting NCT03159104 Phase 3 Tenoten for children;Placebo
17 Total Neoadjuvant Treatment vs. Chemoradiotherapy in Local Advanced Rectal Cancer With High Risk Factors Recruiting NCT03177382 Phase 3 Adjuvant chemotherapy
18 Trial Studying Maintenance Treatment With Lenalidomide and Dexamethasone Versus Lenalidomide, Dexamethasone and MLN9708 After Autologous Hematopoietic Stem Cell Transplantation in Patients With Newly-diagnosed Symptomatic Multiple Myeloma Recruiting NCT02406144 Phase 3 MLN9708;Lenalidomide;Dexamethasone
19 Non-invasive Repetitive Paraorbital Alternating Current Stimulation Therapy for Aphasia Terminated NCT01277575 Phase 3
20 Online Support Groups for Depression and Anxiety Unknown status NCT01149265 Phase 1, Phase 2
21 Comparison of Methods for the Delivery of Interoceptive Exposure Unknown status NCT01201304 Phase 2
22 Combined Treatment for Patients With Comorbid Substance Use Disorders and Post-traumatic Stress Disorder (PTSD): an Integration of Cognitive-behavioral Treatment (CBT) and Trauma-focused Structured Writing Therapy Completed NCT00763542 Phase 2
23 Exercise Interventions in Parkinson's Disease Completed NCT01439022 Phase 2
24 Study Targeting Affect Regulation Completed NCT01237366 Phase 1, Phase 2
25 Pilot Trial of Botulinum Toxin and Occupational Therapy for Writer's Cramp Completed NCT02015039 Phase 1, Phase 2 BoNT Injections
26 Propranolol in Post Traumatic Stress Disorder Completed NCT00465608 Phase 2 propranolol
27 Building Complex Language Completed NCT01337232 Phase 1, Phase 2
28 Motor Training to Treat Hand Dystonia Completed NCT00021853 Phase 2
29 Transcranial Electrical Polarization to Treat Focal Hand Dystonia Completed NCT00106782 Phase 2
30 Girls In Recovery From Life Stress (GIRLS) Study Completed NCT00751946 Phase 2
31 Volitional Swallowing in Stroke Patients With Chronic Dysphagia Completed NCT00306501 Phase 2
32 Mothers Overcoming and Managing Stress Completed NCT00751244 Phase 2
33 Pain and Stress Management for People With Rheumatoid Arthritis Completed NCT00088764 Phase 2
34 Pioglitazone to Treat Fatty Liver in People With HIV Infection Completed NCT00441272 Phase 2 Pioglitazone
35 Positive Psychology Interventions in Individuals With Chronic Pain and Spinal Cord Injury Completed NCT02459028 Phase 2
36 Higher Dose Intradermal H5 Vaccine Completed NCT00439335 Phase 1, Phase 2 Placebo (IM);Placebo (ID)
37 Open Label Evaluation of H5N1 Vaccine at Vaccine Manufacturing Facilities Completed NCT00311649 Phase 1, Phase 2
38 Pain and Stress Management for Fibromyalgia Completed NCT01287481 Phase 2
39 My Scrivener® - Measuring Effectiveness and Dose Response in Children Completed NCT00919906 Phase 1, Phase 2
40 Expressive Writing for Reducing Stress and Diabetic Symptoms in Diabetes Patients Completed NCT00233142 Phase 2
41 NAET® Testing Devices in Detection of Hypersensitivity to Cane Sugar Completed NCT00292578 Phase 1, Phase 2
42 Low Vision Study Comparing EV Training vs. CCTV for AMD Rehabilitation Completed NCT00971464 Phase 2
43 Functional Connectivity as a Biomarker of rTMS Recruiting NCT03050801 Phase 1, Phase 2
44 Remote Ischemic Preconditioning of Human Myocardium Recruiting NCT01994707 Phase 2
45 Phase 1-2 Study of ASTX660 in Subjects With Advanced Solid Tumors and Lymphomas Recruiting NCT02503423 Phase 1, Phase 2 ASTX660
46 Oral Pazopanib Plus Oral Topotecan Metronomic Antiangiogenic Therapy for Recurrent Glioblastoma Multiforme (A) Without Prior Bevacizumab Exposure and (B) After Failing Prior Bevacizumab Not yet recruiting NCT01931098 Phase 2 topotecan;pazopanib
47 Zevalin Twice in Aggressive Non-Hodgkin Lymphoma Terminated NCT00902525 Phase 2 90Y-Ibritumomab Tiuxetan
48 R-CHOP and Alemtuzumab in Patients With Chronic Lymphocytic Leukemia Withdrawn NCT00504491 Phase 2 Rituximab-CHOP-Alemtuzumab
49 Far Infrared Irradiation for Stroke Rehabilitation Unknown status NCT00675155 Phase 1
50 Effects of Music Therapy on Huntington's Disease Completed NCT00178360 Phase 1

Search NIH Clinical Center for Writing Disorder

Genetic Tests for Writing Disorder

Anatomical Context for Writing Disorder

MalaCards organs/tissues related to Writing Disorder:

39
Brain, Testes, Liver, Heart, Lung, Kidney, Spinal Cord

Publications for Writing Disorder

Articles related to Writing Disorder:

id Title Authors Year
1
The Ege Agraphia Test Battery for Identifying the Writing Disorders in Cases with Mild Cognitive Impairment and Alzheimer's Disease. ( 27711939 )
2016
2
Development of visual-motor perception in pupils with expressive writing disorder and pupils without expressive writing disorder: a comparative statistical analysis. ( 24791121 )
2013
3
Long-term psychosocial and health economy consequences of ADHD, autism, and reading-writing disorder: a prospective service evaluation project. ( 17968030 )
2008
4
Writing through the phonological buffer: a case of progressive writing disorder. ( 15949512 )
2005
5
Neurocognitive stability in Asperger syndrome, ADHD, and reading and writing disorder: a pilot study. ( 11263686 )
2001
6
Writing disorders in Italian aphasic patients. A multiple single-case study of dysgraphia in a language with shallow orthography. ( 9762960 )
1998
7
A model of writing performance: evidence from a dysgraphic patient with an "allographic" writing disorder. ( 4041261 )
1985

Variations for Writing Disorder

Expression for Writing Disorder

Search GEO for disease gene expression data for Writing Disorder.

Pathways for Writing Disorder

GO Terms for Writing Disorder

Biological processes related to Writing Disorder according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 neuron migration GO:0001764 9.16 DCDC2 PSEN1
2 neutrophil degranulation GO:0043312 9.13 CAMP GRN PSEN1
3 intracellular signal transduction GO:0035556 8.8 DCDC2 MAP4K5 PSEN1

Sources for Writing Disorder

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....